posted
I ran across this list, if any of you are interested:
NVAX uses a virus-like particle platform technology for infectious diseases including multiple strains of influenza, H5N1, shingles and Respiratory Syncytial Virus.
ADLS has a leading candidate called Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pnemonia. It’s also completed Phase III clinical trials for the treatment of respiratory tract infections.
BCRX engages in the design, optimization, and development of novel drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.
GNVC is developing a product called TherAtoh, a potential vaccination for respiratory syncytial virus, HSV-2, malaria, HIV and foot-and-mouth disease.
DVAX products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases.
HEB develops multiple products for the treatment of West Nile Virus, SARS, genital wards and Myalgic Encephalomyelitis / Chronic Fatigue Syndrome.
HGSI development pipeline includes drugs to treat inhalation anthrax, hepatitis C and lupus.
IMM programs include hepatitis C virus, fungal diseases, and multi-drug resistant strains of bacterial infections.
INHX develops anti-infective products to treat serious infections including shingles, chicken pox and herpes.
INSM engages in the development of recombinant protein drugs. Their IPLEX product is a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions.
SVA engages in the sale of vaccines that protect against human infectious diseases primarily in China. Their Anflu drug provides a split virus influenza vaccine.
VICL develops products based on its DNA delivery technologies for the prevention and treatment of diseases including H5N1 pandemic influenza virus and cytomegalovirus.
MCET has a $1.4M market cap and is trading at $0.01. According to the company’s website, their MCT-465 drug candidate is a Toll-like Receptor (TLR) agonist, and is indicated as prospective therapy for treatment of virus infections including influenza A H1N1 and the “avian flu” virus.
HALO has a treatment called Gammagard. It’s a sterilized solution made from human plasma that contains the antibodies to help your body protect itself against infection from various diseases. A $30 billion company, Baxter International (BAX), has partnered with HALO for the distribution of Gammagard and must pay royalties for its use.
AVII is developing drugs for the treatment of rare viruses and conducts research in collaboration with the U.S. Army. The majority of this collaboration has been supported by a research contract from the Department of Defense’s Transformational Medical Technologies Iniative with the goal of developing new antiviral drugs.
XOMA is currently engaged in more than 16 active development projects across multiple therapeutic areas including autoimmune and infectious disease. The company has ongoing contracts with the National Institutes of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID) to develop monoclonal antibody products.
LWLLE is engaged in the development, manufacture, sale and distribution of disinfectant health care products including hand disinfectants, surface disinfectants, equipment disinfectants, machine disinfectants and animal disinfectants.
Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
